{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:33:04Z","timestamp":1781195584230,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008143","name":"Oregon National Primate Research Center","doi-asserted-by":"publisher","award":["8P51 OD011092-53"],"award-info":[{"award-number":["8P51 OD011092-53"]}],"id":[{"id":"10.13039\/100008143","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01 AI082196"],"award-info":[{"award-number":["U01 AI082196"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R44 AI079898"],"award-info":[{"award-number":["R44 AI079898"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.vaccine.2016.11.080","type":"journal-article","created":{"date-parts":[[2016,12,3]],"date-time":"2016-12-03T19:15:22Z","timestamp":1480792522000},"page":"283-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine"],"prefix":"10.1016","volume":"35","author":[{"given":"Elizabeth A.","family":"Poore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn K.","family":"Slifka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Rau\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Hammarlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin K.","family":"Quintel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay L.","family":"Torrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel M.","family":"Slifka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Richner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa E.","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence P.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Slifka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J.","family":"Amanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.11.080_b0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7774\/cevr.2014.3.1.58","article-title":"Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses","volume":"3","author":"Go","year":"2014","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.vaccine.2016.11.080_b0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.ento.53.103106.093258","article-title":"A global perspective on the epidemiology of West Nile virus","volume":"53","author":"Kramer","year":"2008","journal-title":"Annu Rev Entomol"},{"key":"10.1016\/j.vaccine.2016.11.080_b0015","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1086\/656602","article-title":"West Nile fever characteristics among viremic persons identified through blood donor screening","volume":"202","author":"Zou","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.11.080_b0020","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/14760584.2014.906309","article-title":"Current trends in West Nile virus vaccine development","volume":"13","author":"Amanna","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.11.080_b0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4269\/ajtmh.13-0432","article-title":"Lack of evidence of increased West Nile virus disease severity in the United States in 2012","volume":"90","author":"Lindsey","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2016.11.080_b0030","doi-asserted-by":"crossref","first-page":"12941","DOI":"10.1128\/JVI.77.24.12941-12949.2003","article-title":"Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice","volume":"77","author":"Engle","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.080_b0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1086\/376870","article-title":"Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice","volume":"188","author":"Ben-Nathan","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.11.080_b0040","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nm1240","article-title":"Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus","volume":"11","author":"Oliphant","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2016.11.080_b0045","doi-asserted-by":"crossref","first-page":"14606","DOI":"10.1128\/JVI.79.23.14606-14613.2005","article-title":"Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus","volume":"79","author":"Gould","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.080_b0050","doi-asserted-by":"crossref","first-page":"12149","DOI":"10.1128\/JVI.01732-06","article-title":"Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein","volume":"80","author":"Oliphant","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.080_b0055","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1128\/JVI.00551-06","article-title":"Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus","volume":"80","author":"Throsby","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.080_b0060","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.vaccine.2008.02.009","article-title":"The relative contribution of antibody and CD8(+) T cells to vaccine immunity against West Nile encephalitis virus","volume":"26","author":"Shrestha","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.080_b0065","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/nm.2763","article-title":"Development of a new hydrogen peroxide-based vaccine platform","volume":"18","author":"Amanna","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2016.11.080_b0070","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/JVI.02903-12","article-title":"A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal west Nile virus infection in aged mice","volume":"87","author":"Pinto","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.080_b0075","unstructured":"WHO. Requirements for the use of animal cells as in vitro substrates for the production of biologicals (Addendum 2003). In: WHO, editor. Geneva: WHO; 2005. p. 135\u20137."},{"key":"10.1016\/j.vaccine.2016.11.080_b0080","doi-asserted-by":"crossref","first-page":"9424","DOI":"10.1128\/JVI.00768-06","article-title":"Resistance to alpha\/beta interferon is a determinant of West Nile virus replication fitness and virulence","volume":"80","author":"Keller","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.080_b0085","doi-asserted-by":"crossref","first-page":"7704","DOI":"10.1128\/JVI.00401-12","article-title":"Infectious clones of novel lineage 1 and lineage 2 West Nile virus strains WNV-TX02 and WNV-Madagascar","volume":"86","author":"Suthar","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.080_b0090","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity","volume":"28","author":"Monath","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.080_b0095","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4161\/hv.2.4.2989","article-title":"Evaluation of the thermal stability of Gardasil","volume":"2","author":"Shank-Retzlaff","year":"2006","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2016.11.080_b0100","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3201\/eid0704.017418","article-title":"The relationships between West Nile and Kunjin viruses","volume":"7","author":"Scherret","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.11.080_b0105","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/viro.2002.1449","article-title":"Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East","volume":"298","author":"Lanciotti","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.11.080_b0110","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1038\/emboj.2009.245","article-title":"Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody","volume":"28","author":"Cherrier","year":"2009","journal-title":"EMBO J"},{"key":"10.1016\/j.vaccine.2016.11.080_b0115","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nature03956","article-title":"Structural basis of West Nile virus neutralization by a therapeutic antibody","volume":"437","author":"Nybakken","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.11.080_b0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1258\/la.2009.009042","article-title":"Kinetics of {alpha}2-macroglobulin and {alpha}1-acid glycoprotein in rats subjected to repeated acute inflammatory stimulation","volume":"44","author":"Honjo","year":"2010","journal-title":"Lab Anim"},{"key":"10.1016\/j.vaccine.2016.11.080_b0125","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1086\/381461","article-title":"Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection","volume":"189","author":"Ratterree","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.11.080_b0130","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0950268812001070","article-title":"Estimated cumulative incidence of West Nile virus infection in US adults, 1999\u20132010","volume":"141","author":"Petersen","year":"2013","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2016.11.080_b0135","unstructured":"Centers for disease control and prevention. West Nile virus disease cases and deaths reported to CDC by year and clinical presentation; 1999\u20132015. https:\/\/www.cdc.gov\/westnile\/statsmaps\/cummapsdata.html. [accessed Oct 6, 2016]."},{"key":"10.1016\/j.vaccine.2016.11.080_b0140","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1073\/pnas.1834270100","article-title":"DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus","volume":"100","author":"Hall","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.11.080_b0145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4269\/ajtmh.2005.72.99","article-title":"Variation in virulence of West Nile virus strains for house sparrows (Passer domesticus)","volume":"72","author":"Langevin","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2016.11.080_b0150","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3201\/eid1012.040486","article-title":"Differential virulence of West Nile strains for American crows","volume":"10","author":"Brault","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.11.080_b0155","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1099\/vir.0.81306-0","article-title":"CD8(+) T cell-mediated immune responses in West Nile virus (Sarafend strain) encephalitis are independent of gamma interferon","volume":"87","author":"Wang","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.11.080_b0160","series-title":"Biosafety in microbiological and biomedical laboratories","author":"Centers for Disease Control and Prevention","year":"2009"},{"key":"10.1016\/j.vaccine.2016.11.080_b0165","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1016\/S0264-410X(01)00208-0","article-title":"A purified inactivated Japanese encephalitis virus vaccine made in Vero cells","volume":"19","author":"Srivastava","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.080_b0170","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.virol.2009.10.023","article-title":"Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy","volume":"396","author":"Simmons","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.11.080_b0175","first-page":"137","article-title":"Experience with vero cells at Pasteur Merieux Connaught","volume":"98","author":"Montagnon","year":"1999","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2016.11.080_b0180","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/192535a0","article-title":"Biochemical aspects of phagocytosis","volume":"192","author":"Iyer","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.11.080_b0185","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0304-4165(68)90116-5","article-title":"The role of the phagocyte in host-parasite interactions. 13. The direct quantitative estimation of H2O2 in phagocytizing cells","volume":"156","author":"Paul","year":"1968","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.vaccine.2016.11.080_b0190","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3382\/ps.0731511","article-title":"The effect of microaerosolized hydrogen peroxide on bacterial and viral poultry pathogens","volume":"73","author":"Neighbor","year":"1994","journal-title":"Poult Sci"},{"issue":"Pt 2","key":"10.1016\/j.vaccine.2016.11.080_b0195","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S0031182000057309","article-title":"A study of the sensitivity of Leishmania donovani promastigotes and amastigotes to hydrogen peroxide. I. Differences in sensitivity correlate with parasite-mediated removal of hydrogen peroxide","volume":"91","author":"Channon","year":"1985","journal-title":"Parasitology"},{"key":"10.1016\/j.vaccine.2016.11.080_b0200","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1472-765X.2007.02283.x","article-title":"Disinfection of Bacillus subtilis spore-contaminated surface materials with a sodium hypochlorite and a hydrogen peroxide-based sanitizer","volume":"46","author":"DeQueiroz","year":"2008","journal-title":"Lett Appl Microbiol"},{"key":"10.1016\/j.vaccine.2016.11.080_b0205","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/jac\/dkq308","article-title":"Mode of action of hydrogen peroxide and other oxidizing agents: differences between liquid and gas forms","volume":"65","author":"Finnegan","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.vaccine.2016.11.080_b0210","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/prca.200780009","article-title":"Oxidation of proteins: basic principles and perspectives for blood proteomics","volume":"2","author":"Barelli","year":"2008","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.vaccine.2016.11.080_b0215","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0042-6822(69)90158-5","article-title":"Damage, repair, and recombination. II. Effect of hydrogen peroxide on the bacteriophage genome","volume":"38","author":"Yamamoto","year":"1969","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.11.080_b0220","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0027-5107(97)00141-3","article-title":"Reactive oxygen species-induced DNA damage and its modification: a chemical investigation","volume":"379","author":"Yu","year":"1997","journal-title":"Mutat Res"},{"key":"10.1016\/j.vaccine.2016.11.080_b0225","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1126\/science.aaa4919","article-title":"An Ebola whole-virus vaccine is protective in nonhuman primates","volume":"348","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.11.080_b0230","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0065-3527(03)61010-9","article-title":"Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines","volume":"61","author":"Eckels","year":"2003","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.vaccine.2016.11.080_b0235","first-page":"221","article-title":"Equine vaccine for West Nile virus","volume":"114","author":"Ng","year":"2003","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2016.11.080_b0240","series-title":"IXIARO package insert","author":"Intercell-AG","year":"2013"},{"key":"10.1016\/j.vaccine.2016.11.080_b0245","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1016\/j.vaccine.2010.05.069","article-title":"Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.080_b0250","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1016\/j.vaccine.2015.05.037","article-title":"Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis","volume":"33","author":"Paulke-Korinek","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.080_b0255","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1016\/j.vaccine.2014.06.028","article-title":"Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety","volume":"32","author":"Beran","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.080_b0260","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/jama.2013.8042","article-title":"West Nile virus: review of the literature","volume":"310","author":"Petersen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2016.11.080_b0265","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.coviro.2012.01.004","article-title":"Licensure of vaccines using the animal rule","volume":"2","author":"Burns","year":"2012","journal-title":"Curr Opin Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16311513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16311513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:24:20Z","timestamp":1759400660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16311513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0264410X16311513"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.080","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}